Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04991779
Other study ID # CHFudanU_NNICU16
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date March 16, 2022
Est. completion date May 16, 2022

Study information

Verified date December 2023
Source Children's Hospital of Fudan University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A diagnostic accuracy study on Artificial intelligence assisted continue EEG diagnostic tool is to carried out comparing with manually EEG interpretation as the golden standard for neonatal seizure.


Description:

The occurrence of neonatal seizures may be the first, and perhaps the only, clinical sign of a central nervous system disorder in the newborn infant. The incidence of neonatal seizures is variable based on gestational age. The etiology of seizures may indicate the presence of a potentially treatable etiology and should prompt an immediate evaluation to determine the cause and to initiate etiology-specific therapy. Importantly, the earlier treatment of seizures positively affects the infant's long-term neurological development. However, even when continue electroencephalogram (cEEG) monitoring is available, the availability of on-site expertise to interpret cEEG signals is limited and in practice, the diagnosis is still based only on clinical signs. The previous study indicated that the reliable seizure detection was as little as 10% of seizure events. Therefore, an early automated seizure detection tool has been developed based on machine learning. The lack of an automated seizure detection tool has been validated in the external neonatal seizures cohort. The evidence on the utility of the automated seizure detection tool remains uncertain. This is a prospective, continuous double-blind designed diagnostic accuracy study. The study aims to validate the accuracy of the artificial intelligence (AI)-assisted cEEG diagnostic tool comparing the manually cEEG interpretation as the golden standard of neonatal seizure in neonatal intensive care units. Analysis of sensitivity and specificity is to evaluate the accuracy of AI-assisted cEEG diagnostic tool.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 16, 2022
Est. primary completion date May 16, 2022
Accepts healthy volunteers No
Gender All
Age group 0 Days to 28 Days
Eligibility Inclusion Criteria: - Postnatal age < or = 28 days; - cEEG monitoring at least 12hours monitoring; - Suspected seizures; - Risk of Intracranial hemorrhage; - Abnormality of MRI or ultrasound before cEEG; - Neonates diagnosed with encephalopathy or suspected of encephalopathy; - Hypoxic-ischemic encephalopathy or suspected hypoxic-ischemic encephalopathy; - Metabolic disturbances (Hypoglycemia, Hypocalcemia, Hypomagnesemia, Inborn errors of metabolism); - Central nervous system (CNS) or systemic infections; - Postsurgical neonatal within 3 days; - Suspected genetic disease or Positive genetic diagnoses; Exclusion Criteria: - The neonates with head scalp defect, scalp hematoma, edema and other contraindications which are not suitable for cEEG monitoring during hospitalization.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
AI-assisted cEEG detection tool
This study is an observational study to evaluate the accuracy of AI-assisted cEEG diagnostic tool with routine care. All patients from the cohort accept cEEG monitoring and AI-assisted cEEG detection tool. The tool included a quantitive EEG neural signal processing pipeline to extract features from the original signal datasets, machine learning models based on gradient boosted model for prediction. The reference standard is the electrographic seizures interpreted by 3 clinicians who had attended the uniformly training program and were certified by the Chinese Anti-Epilepsy Association.

Locations

Country Name City State
China Chengdu Women's and Children's Central Hospital Chengdu Sichuan
China Children Hospital of Fudan University Shanghai Shanghai
China Henan Children's Hospital Zhengzhou Henan

Sponsors (4)

Lead Sponsor Collaborator
Children's Hospital of Fudan University Chengdu Women's and Children's Central Hospital, Kunming Children's Hospital, Xiamen Children's Hospital

Country where clinical trial is conducted

China, 

References & Publications (3)

Hoodbhoy Z, Masroor Jeelani S, Aziz A, Habib MI, Iqbal B, Akmal W, Siddiqui K, Hasan B, Leeflang M, Das JK. Machine Learning for Child and Adolescent Health: A Systematic Review. Pediatrics. 2021 Jan;147(1):e2020011833. doi: 10.1542/peds.2020-011833. Epub — View Citation

Rennie JM, de Vries LS, Blennow M, Foran A, Shah DK, Livingstone V, van Huffelen AC, Mathieson SR, Pavlidis E, Weeke LC, Toet MC, Finder M, Pinnamaneni RM, Murray DM, Ryan AC, Marnane WP, Boylan GB. Characterisation of neonatal seizures and their treatmen — View Citation

Shellhaas RA, Chang T, Tsuchida T, Scher MS, Riviello JJ, Abend NS, Nguyen S, Wusthoff CJ, Clancy RR. The American Clinical Neurophysiology Society's Guideline on Continuous Electroencephalography Monitoring in Neonates. J Clin Neurophysiol. 2011 Dec;28(6 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The accuracy of AI-assisted cEEG diagnostic tool in evaluating the neonatal seizure The accuracy of includes sensitivity and specificity. The reference standard is the electrographic seizures interpreted by 3 clinicians who had attended the uniformly training program and were certified by the Chinese Anti-Epilepsy Association.
Sensitivity is defined as: The proportion of neonates with seizures is successfully screened out by AI-assisted cEEG diagnostic tool.
Specificity is defined as: The proportion of neonates without seizures who are not recognized as seizures by AI-assisted cEEG diagnostic tool.
within 7 days since the end of cEEG monitoring during hospitalization
See also
  Status Clinical Trial Phase
Recruiting NCT05127070 - Evaluating the NeoTree in Malawi and Zimbabwe
Withdrawn NCT03602118 - Study to Evaluate Phenobarbital Sodium Injection for the Treatment of Neonatal Seizures Phase 3
Not yet recruiting NCT04831242 - Monitoring Key Activity and Physiology of Neonates in Intensive Care
Completed NCT01224457 - Effect of CYP2C9/CYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korean Neonatal Seizure Patients. N/A
Recruiting NCT05610085 - A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures Phase 2
Recruiting NCT05036395 - The Effect of AI-assisted cEEG Diagnosis on the Administration of Antiseizure Medication in Neonatal Seizures N/A
Active, not recruiting NCT04337697 - Neonatal Seizure Registry - Developmental Functional EValuation
Withdrawn NCT03996317 - Maternal Hyperoxygenation for Intrapartum Fetal Heart Rate Tracing Abnormalities N/A
Active, not recruiting NCT06308185 - Neonatal Seizures: Semiology, Etiology, Therapy and Prognosis Correlations
Not yet recruiting NCT05257889 - Neonatal Seizures in NICU of Assuit University Children's Hospital
Not yet recruiting NCT03786497 - Protecting Brains and Saving Futures - the PBSF Protocol
Completed NCT06211192 - What Are the Determinant Factors of Ceasing Anti-seizure Medication in Infants With Neonatal Seizures?
Completed NCT01747863 - Prospective Research in Infants With Mild Encephalopathy N/A
Active, not recruiting NCT04259125 - Evaluating the Role of Inflammation in Neonatal Epileptogenesis
Recruiting NCT05361070 - Neonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy